Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL-1706 with PLDR in Recurrent/Metastatic Tumors
NCT06760676Phase 1Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Dec 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of iparomlimab + tuvonralimab in esophageal cancer, non-small cell lung cancer (NSCLC) and Cervical Cancer (CC), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Objective Response Rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
esophageal cancernon-small cell lung cancer (NSCLC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06760676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760676.